Myclausen (Mycophenolate Mofetil)

Mycophenolate mofetil is converted in the body to mycophenolic acid, which selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This blocks guanosine nucleotide synthesis, a pathway essential for the proliferation of activated T and B lymphocytes, thereby reducing immune‑mediated damage.

The dosing regimen for Myclausen is individualized by the treating physician based on the specific transplant type, renal function, and patient tolerance. Only a qualified prescriber can determine the appropriate dose and schedule.

Myclausen’s pregnancy category is listed as unknown, and limited data exist on its safety in lactation. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To request Myclausen, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and necessary import documentation.

The primary alternative to mycophenolate mofetil is azathioprine, another antimetabolite immunosuppressant. Myclausen generally offers more potent inhibition of lymphocyte proliferation with a different side‑effect profile, while azathioprine may be preferred in patients with specific tolerability concerns or drug‑interaction considerations.

Myclausen should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Myclausen is taken orally, usually with a glass of water. It can be administered with or without food, but consistent intake with respect to meals helps maintain stable absorption. Patients should follow the prescriber’s instructions regarding timing and any dose adjustments.

Serious risks include bone‑marrow suppression leading to anemia, leukopenia or thrombocytopenia; severe or opportunistic infections; liver toxicity; and an increased long‑term risk of certain malignancies. Patients should promptly report signs such as persistent fever, unusual bruising, jaundice or unexplained weight loss.

Myclausen is contraindicated in individuals with known hypersensitivity to mycophenolate mofetil or any of its excipients. Caution is advised for patients with severe bone‑marrow suppression, uncontrolled infections, or significant liver disease. The drug should also be avoided in patients receiving live vaccines due to heightened infection risk.